Sinopharm Tech : 2022 FIRST QUARTERLY REPORT 2021/2022

(Stock Code: 8156)	FIRST QUARTERLY REPORT 2021/2022

CHARACTERISTICS OF GEM ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the "Directors") of Sinopharm Tech Holdings Limited (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 30 SEPTEMBER 2021

RESULTS

The board of Directors of the Company (the "Board") announces that the unaudited consolidated financial results of the Company and its subsidiaries (collectively the "Group") for the three months ended 30 September 2021 (the "Period 2021"), together with the comparative unaudited figures for the corresponding period in 2020 (the "Period 2020"), are as follows:

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

		(Unaudited)
		Three months ended
		30 September
		2021		2020
	Notes	HK$'000	HK$'000
Revenue	2	1,679		46,054
Costs of sales and services		(1,317)	(33,335)
Gross profit		362		12,719
Other income and gains		8,770		1,465
Selling and distribution expenses		(164)	(4,531)
Administrative and operating expenses		(13,772)	(11,250)
Share of profits of associates		62		1,766
Operating (loss)/profit		(4,742)	169
Finance costs		(4,632)	(4,664)
Loss before tax	3	(9,374)	(4,495)
Income tax expense	4	-	(127)
Loss for the period		(9,374)	(4,622)
Loss for the period attributable to:
Equity holders of the Company		(9,395)	(4,635)
Non-controlling interests		21		13
		(9,374)	(4,622)

SINOPHARM TECH HOLDINGS LIMITED FIRST QUARTERLY REPORT 2021/2022

1

QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 30 SEPTEMBER 2021

		(Unaudited)
		Three months ended
		30 September
		2021		2020
	Notes	HK$'000	HK$'000
Other comprehensive (loss)/income
for the period, net of tax:
Items that may be reclassified subsequently to
profit or loss:
Exchange differences arising on translation
of financial statements of overseas
operations		(238)	1,087
Total comprehensive loss for the period		(9,612)	(3,535)
Total comprehensive loss for the period
attributable to:
Equity holders of the Company		(9,633)	(3,612)
Non-controlling interests		21		77
		(9,612)	(3,535)
		HK Cents		HK Cents
Loss per share attributable to equity
holders of the Company	5
Basic		(0.21)	(0.11)
Diluted		N/A		N/A

2	SINOPHARM TECH HOLDINGS LIMITED FIRST QUARTERLY REPORT 2021/2022

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended 30 September 2021

1. BASIS OF PREPARATION AND PRINCIPAL ACCOUNTING POLICIES
2. 
   The unaudited consolidated results have been prepared in accordance with accounting principles generally accepted in Hong Kong which include Hong Kong Financial Reporting Standards ("HKFRSs"), Hong Kong Accounting Standards and Interpretations issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and the applicable disclosure requirements of GEM Listing Rules.
   Except as described below, the accounting policies and methods of computation used in the unaudited consolidated financial results for the three months ended 30 September 2021 are the same as those followed in the preparation of the Group's annual financial statements for the year ended 30 June 2021.
   The Group has adopted all of the new and revised standards, amendments and interpretations which are relevant to its operations and effective for the accounting period beginning on 1 July 2021. The adoption of these new and revised standards, amendments and interpretation does not have significant impact on the accounting policies of the Group, and the amounts reported for the current period and prior periods.
   The Group has not early applied any new and revised HKFRSs that have been issued but are not yet effective.
3. REVENUE
4. 1. 
      The principal activities of the Group are provision of (i) lottery-related services,
   2. internet plus services (solution and supply chain), (iii) manufacturing and distribution of personal protective equipment and (iv) others services.

SINOPHARM TECH HOLDINGS LIMITED FIRST QUARTERLY REPORT 2021/2022

3